These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27564288)

  • 1. Optimal bladder diary duration for patients with suprapontine neurogenic lower urinary tract dysfunction.
    Konstantinidis C; Kratiras Z; Samarinas M; Skriapas K
    Int Braz J Urol; 2016; 42(4):766-72. PubMed ID: 27564288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis of overactive bladder influenced by methods of clinical assessment--micturition diary vs. urodynamics].
    Skorupski P; Tomaszewski J; Adamiak A; Jankiewicz K; Rechberger T
    Ginekol Pol; 2003 Sep; 74(9):1018-22. PubMed ID: 14674162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary.
    Bright E; Cotterill N; Drake M; Abrams P
    Eur Urol; 2014 Aug; 66(2):294-300. PubMed ID: 24647230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-day bladder diary for children: Is it enough?
    Lopes I; Veiga ML; Braga AA; Brasil CA; Hoffmann A; Barroso U
    J Pediatr Urol; 2015 Dec; 11(6):348.e1-4. PubMed ID: 26386888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women.
    Jimenez-Cidre MA; Lopez-Fando L; Esteban-Fuertes M; Prieto-Chaparro L; Llorens-Martinez FJ; Salinas-Casado J; Castro-Diaz D; Müller-Arteaga C; Adot-Zurbano JM; Rodriguez-Escobar F; Gutierrez C; Arlandis-Guzman S; Bonillo-Garcia MA; Madurga-Patuel B; Leva-Vallejo M; Franco de Castro A; Peri-Cusi L; Conejero-Sugrañes J; Jimenez-Calvo J; Rebollo P; Mora A
    Neurourol Urodyn; 2015 Feb; 34(2):128-32. PubMed ID: 24264859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement characteristics of a voiding diary for use by men and women with overactive bladder.
    Brown JS; McNaughton KS; Wyman JF; Burgio KL; Harkaway R; Bergner D; Altman DS; Kaufman J; Kaufman K; Girman CJ
    Urology; 2003 Apr; 61(4):802-9. PubMed ID: 12670569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive outcome measures of urinary incontinence and lower urinary tract symptoms: a multicenter study of micturition diary and pad tests.
    Groutz A; Blaivas JG; Chaikin DC; Resnick NM; Engleman K; Anzalone D; Bryzinski B; Wein AJ
    J Urol; 2000 Sep; 164(3 Pt 1):698-701. PubMed ID: 10953128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder.
    Abrams P; Paty J; Martina R; Newgreen DT; van Maanen R; Paireddy A; Kuipers-deGroot T; Ridder A
    Neurourol Urodyn; 2016 Aug; 35(6):743-9. PubMed ID: 26174907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between voided volume and the urge to void among patients with lower urinary tract symptoms.
    Blaivas JG; Tsui JF; Amirian M; Ranasinghe B; Weiss JP; Haukka J; Tikkinen KA
    Scand J Urol; 2014 Dec; 48(6):554-8. PubMed ID: 25029069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder.
    Chancellor M; Versi E; Dvergsten C; Toler S
    J Urol; 2015 Nov; 194(5):1329-35. PubMed ID: 26073872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are three-day voiding diaries feasible and reliable? Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) cohort.
    Cameron AP; Wiseman JB; Smith AR; Merion RM; Gillespie BW; Bradley CS; Amundsen CL; Yang CC; Lai HH; DeLancey JOL; Helmuth ME; Bradley MS; Agochukwu N; Andreev VP; Kirkali Z; Clemens JQ;
    Neurourol Urodyn; 2019 Nov; 38(8):2185-2193. PubMed ID: 31347211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urodynamic Investigation: A Valid Tool to Define Normal Lower Urinary Tract Function?
    Leitner L; Walter M; Sammer U; Knüpfer SC; Mehnert U; Kessler TM
    PLoS One; 2016; 11(10):e0163847. PubMed ID: 27736908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine production and bladder diary measurements in women with type 2 diabetes mellitus and their relation to lower urinary tract symptoms and voiding dysfunction.
    Fayyad AM; Hill SR; Jones G
    Neurourol Urodyn; 2010 Mar; 29(3):354-8. PubMed ID: 19760759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimal duration of frequency-volume charts related to compliance and reliability.
    van Haarst EP; Bosch JL
    Neurourol Urodyn; 2014 Mar; 33(3):296-301. PubMed ID: 24166989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Women overestimate daytime urinary frequency: the importance of the bladder diary.
    Stav K; Dwyer PL; Rosamilia A
    J Urol; 2009 May; 181(5):2176-80. PubMed ID: 19296975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.